The 2008 edition of this incomparable CNS overview incorporates a unique new evaluation of Big Pharma licensing skills and styles There has never been a review of the Business Development and Licensing practices of the major pharmaceutical companies in the US and Europe with this level of detail and candor. The companies are discussed in terms of their culture, style, and 'user-friendliness' from a small partner viewpoint, and they are graded, from A to F. This review has been assembled from interviews with professionals on both sides of the large and small pharma divide, as well our evaluations of the licensing performance over time of each company. For small and midsize companies thinking about strategy and fit, this information is indispensable. And for Big Pharma Business Development professionals, it offers an opportunity to find out how your organization, attitude, ability to relate, and performance are perceived.

The second section of CNS 2008 compiles NI Research's comprehensive reviews of all major psychiatric and neurological indications, and the therapeutics programs under development. All reviews are fully updated and revised as of May 5, 2008. Addiction Disorders and Bipolar Disorder are included for the first time. This provides strategic planners and Business Development professionals with a complete review of the neuro and psychopharmaceutical universe of therapies in development, in a single searchable pdf. There is nothing else like CNS 2008 Disorders/Therapeutics, at any price.

Our monthly journal covering the cutting-edge therapies being developed for disorders of the central nervous system, including Alzheimer’s, Parkinson’s, stroke, brain injury, schizophrenia, and depression--and the companies pursuing them. It enjoys worldwide readership and kudoes for its ‘no-holds-barred’ evaluations.

$1600 for 1 year subscription

Download order form

The 2009 edition of the Private CNS Company Review will continue the PCNS unique database of information for Business Development professionals evaluating strategic opportunities for inlicensing, outlicensing, M&A, collaboration, and financing. Information and expert opinion regarding private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities. Produced in pdf form for easy searchability. The 2009 edition will review 110+ companies in 160+ pages. Release date November 15.

US$4000
Pre-publication discount price $3400
Pre-publication discount price for purchasers of
CNS 2008: $2800

Download 2007-8 sample listing with order form

Download PCNS 2009 information/order form